Beyond The Lab - How Medicines Become Successful Businesses | Jane Gonnerman - Executive Vice President of Strategy and Corporate Development, Collegium Pharmaceutical
We tend to think that a new medicine's journey begins in the laboratory and ends when the FDA approves it. But there's an enormous part of that journey that most people never see: Who decides which medicines a company should acquire? Which ones are worth billions of dollars? How do you turn an approved drug into a successful commercial product - and ultimately get it into the hands of patients? Today we're going behind the scenes of that process.
Jane Gonnerman is Executive Vice President of Strategy and Corporate Development at Collegium Pharmaceutical ( https://www.collegiumpharma.com/ ), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, where she is helping guide the company's long-term growth strategy and business development initiatives.
Before joining Collegium in 2025, Jane served as Senior Vice President of Rare Disease at Amgen following the landmark $28 billion acquisition of Horizon Therapeutics - one of the largest biotechnology acquisitions in recent history. Prior to that, she served as Senior Vice President of Corporate Development and Chief of Staff to Horizon's CEO, playing a central role in the company's corporate strategy, partnerships, acquisitions, and ultimately its successful sale to Amgen.
Earlier in her career, Jane spent more than fifteen years at Bain & Company, becoming a Partner in the firm's healthcare practice where she advised many of the world's leading life science organizations on strategy, growth, organizational transformation, and innovation.
Jane holds an MBA from the University of Chicago Booth School of Business along with dual bachelor's degrees in Mathematics and Statistics from the University of Florida.
Today we'll explore what it really takes to build successful biopharmaceutical companies, how commercialization has become as innovative as science itself, and why strategy may ultimately determine which medical breakthroughs change patients' lives.
Podden och tillhörande omslagsbild på den här sidan tillhör
Ira Pastor. Innehållet i podden är skapat av Ira Pastor och inte av,
eller tillsammans med, Poddtoppen.
